Connect with us


CBD Oil and Psoriasis



We have covered extensively the fact that the endocannabinoid system is intimately integrated into a number of different important systems that drive human physiology.

In today’s examination, were going to take a look at the potential for endocannabinoid-based therapy to impact the experience of those suffering from psoriasis.

To reach our target goal, we first need to understand more about psoriasis.

Understanding Psoriasis

Psoriasis manifests itself through an individual’s experience of itchy, scaly, painful, and flaky skin. When this type of experience becomes chronic in manifest form, it is known as psoriasis.

Psoriasis is actually an autoimmune disease that is ultimately caused by genetic factors. Individuals with a genetic predisposition toward the development of psoriasis can be thought of as having psoriasis in a latent form. Onset of a manifest form of psoriasis must be provoked by external factors in one’s experience.

Psoriasis is most commonly experienced by young adults, although it can be experienced by individuals of any age. It’s incidence is growing, as well. In fact, experts now believe that psoriasis will soon become the most common skin disease for human beings.

One of the issues that makes researching and understanding psoriasis difficult is that studies involving animals don’t seem to be successful.

Nonetheless, research has moved forward. At this point, we have come to believe that psoriasis is ultimately driven by an overactive immune response, with a central role played by T-lymphocytes found in the skin.

More recently, data has also suggested an important role played by inflammatory cytokines.

As noted above, a genetic predisposition is understood to be central to the onset of psoriasis. Genetic researchers have narrowed down the culprits to two particular genes that may be most integral to this predisposition: SLC9A3R1 and NAT9.

These two genes are separated by well over 5 million base pairs on the longer segment of the 17th chromosome. As such, it would appear as though each of these genes contributes independently to the development of psoriasis.

The Endocannabinoid System and Psoriasis

As noted above, and in many places, the endocannabinoid system plays a central role in regulating various bodily processes. The immune system is one of its most important regulatory roles.

Given the important role that the immune system, in turn, plays in driving both inflammation and psoriasis, it should come as no surprise that research has begun to show that receptors that form the backbone of the endocannabinoid system can play a major role in impacting the experience of individuals suffering from psoriasis.

The important point is this: immune cells that are tied into the manifestation of psoriasis can be retroactively inhibited by the triggering of receptors in the endocannabinoid system. When this happens, both the inflammatory and immune response can be mitigated, thus reducing the manifest symptomology we most closely associate with psoriasis.

While there is certainly a need for further research to more deeply understand the processes involved in the potential for cannabinoids such as CBD to play a major role in treatment and therapy for those suffering from psoriasis, the data that we already have makes a strong case that psoriasis patients now have an important weapon in their fight.


CannTrust Holdings Inc (NYSE:CTST) Penetrates Into The United States After Investing $20 Million



CannTrust Holdings Inc (NYSE:CTST), a Canadian company that produces and sells medical and recreational marijuana has announced the expansion of its business into the United States.

The Canadian firm revealed that it signed a Letter of Intent through which it will start working with Elk Grove Farming Company, LLC to access more than 3,000 hemp production acres in California. The two companies struck a joint partnership that will allow CannTrust to secure a footing in the California market which is one of the biggest cannabis markets in the U.S.

“This agreement represents another bold move for CannTrust. Our U.S. operation is expected to deliver a significant increase in low-cost production capacity,” stated CannTrust CEO Peter Aceto.

CannTrust is financially ready to tap into the U.S market

The CannTrust CEO also noted that the company will take advantage of its experience in the formulation of standardized CBD products as part of its strategy to enter the U.S market. Mr. Aceto also revealed that his company’s successful equity offering provided enough financial muscle to fuel its ambitious expansion plans.

CannTrust aims to be among the leading and trusted suppliers of high-quality, standardized CBD formulations derived from hemp. The company believes that there will be an increasing demand for high-grade CBD formulations from international retailers. It therefore makes sense to invest in processes that will add value to the end product such as genetic studies and expert growing practices to achieve the highest safety and quality standards.

Elk Grove and CannTrust will each have 50% ownership in their joint operations. Elk Grove is an ideal partner for the endeavor because it has years of farming experience in a variety of products. Its focus includes products designed for crop protection, supply, and input. Its operations are distributed across California, which means that the groundwork has already been laid for the partnership. It will thus be easier for the CannTrust to penetrate into the California market.

Elk Grove executive Morgan Houchin stated that his company was excited about the partnership with CannTrust. He added that his firm’s experience in farming operations will be a great combination with CannTrust’s experience in creating class-leading formulations.

Continue Reading


Rocky Mountain High Brands Inc (OTCMKTS:RMHB) Strikes Broker Deal With Carlin Group



Lifestyle brand management firm Rocky Mountain High Brands Inc (OTCMKTS:RMHB) announced on Wednesday that it secured a broker deal with Carlin Group for its products in the retail space.

The broker agreement will allow Carlin to represent RMHB’s CBD-infused drinks through the HEMPd brand. It will also represent beverages infused with Hempseed extract under RMHB brands. The deal will also cover CBD-infused wellness products such as lotions, water-soluble solutions, capsules, gummies and tinctures as part of the HEMPd brand. Spirit Water will also be covered under the agreement.

The RMHB-Carlin broker deal covers multiple states. They include Missouri, Nebraska, Texas, South Dakota, North Dakota, Minnesota, Wisconsin, Illinois, Pennsylvania, Tennessee, Kentucky, Ohio, Indiana, and Michigan.

“We are very excited about the opportunity to have our entire product line represented by Carlin Group,” stated RMHB CEO Michael Welch.

The Carlin broker deal will boost RMHB’s exposure

Welch noted that the broker deal will strategically allow RMHB to leverage optimal exposure to mass marketers, grocery store chains, convenient stores, major retailers and other types of outlets. The company would not have managed to reach such a wide range of outlets cost-effectively without a broker deal.

The RMHB CEO also added that his company and Carlin will maintain a close collaboration so that they can facilitate retail availability of RMHB products. Welch also revealed that RMHB reviewed numerous other retail introduction options. This was before settling on Carlin which the company believes is the best-suited brand to rapidly get its products onto retail shelves.

Carlin Group’s Managing Director Albert Vergilio noted in a statement that his company was excited to host RMHB and the CBD-based products that are part of its HEMPd brand in Carlin’s new CBD division. He also added that it is part of investing in the future of CBD considering the fast-tracked popularity of CBD products, and the regulations that govern them.

Carlin’s sales team will undergo some training to get them acquainted with RMBH’s products. The sales team will then hold meetings with corporate customers as part of the retail rollout of the products. Sales that will be part of the broker deal are expected to kick off in Q3.

Continue Reading


Wildflower Brands Inc (OTCMKTS:WLDFF) Establishes Footprint Across The US With PO For Hemp CBD Products From Dillard’s Department Stores And Eyes Markets In Texas And Florida



Wildflower Brands Inc (OTCMKTS:WLDFF) has announced establishing a nationwide presence with a PO from Dillard’s Department store. The company has fulfilled the PO received from Dillard.

Hemp CBD products in 292 locations

Dillard’s department store will showcase the premium hemp CBD products of Wildflower in its 292 locations across the US. With its best practices and transparency, Wildflower is eyeing the key markets in Texas and Florida. The company will educate the customers in these regions about salable products. Wildflower has received subsequent orders from Dillard’s and is fulfilling the requirements.

Chief Executive Officer of Wildflower, William Maclean said the supply of CBD infused products to Dillard’s Department stores doubles the existing retail locations in the nation. The company aims to capitalize on its brand to become a household name. It will improve loyalty building because of the reputation and respect of Dillard’s as a retailer. Wildflower aims to provide health and wellness benefits of its CBD infused products to the customers in the US through Dillard’s.

Signs a deal with Highmark Interactive

Wildflower has signed a deal to use EQ – Brain Tracking, mobile software of Highmark Interactive, in the clinical research to study the functional neurological and cognitive effects of CBD. The company aims to get meaningful results and data that help to understand the functional and cognitive neurological properties of the cannabinoids.

William said the company would collect testimonials from the customers on its products that provide the health and wellness needs using plant-based solutions. The company will strive to improve the products, and the research helps it to reach that goal and growth with continued investments.

Acquires City Cannabis Corp

Wildflower has signed an LOI on April 3, 2019, to take over City Cannabis Corp. The company will issue its 60 million common shares for the takeover. The companies will complete the acquisition on receiving advice from corporate, tax, and securities law departments.

The cannabis retailer City Cannabis holds two licenses in the City of Vancouver to market cannabis. It is generating profits through operating dispensaries in Vancouver. The acquisition helps Wildflower to expand retail footprint using the expertise of City Cannabis.

Continue Reading

Trending Stories